<br />
EUROPEAN MEDICAL JOURNAL<br />
ISSN 2397-6764 Vol 2.1 • March 2017 • europeanmedical-journal.com<br />
CONTENTS<br />
EDITORIAL BOARD...................................................................................................................................... 4<br />
FEATURE<br />
• CLIMATE CHANGE: WHAT CAN DOCTORS DO?............................................................................. 12<br />
Thomas Micklewright<br />
ARTICLES<br />
• EDITOR’S PICK: 3D PRINTING FOR BIOMEDICAL APPLICATIONS:<br />
WHERE ARE WE NOW?........................................................................................................................ 16<br />
Carlos Miguel Chiesa Estomba et al.<br />
• HIDE AND SEEK: THE GAME BETWEEN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS<br />
AND B CELL RECEPTOR SIGNALLING INHIBITORS……………………………………………………............ 24<br />
Kumudha Balakr<a title="EMJ 2.1 2017 page 1" href="http://viewer.zmags.com/publication/f42cbf2e?page=1"> EUROPEAN MEDICAL JOURNAL ISSN 2397-6764 </a>
<a title="EMJ 2.1 2017 page 2" href="http://viewer.zmags.com/publication/f42cbf2e?page=2"> CONTENTS EDITORIAL BOARD.......................</a>
<a title="EMJ 2.1 2017 page 3" href="http://viewer.zmags.com/publication/f42cbf2e?page=3"> EUROPEAN MEDICAL JOURNAL • ANAESTHESIA TECHNIQ</a>
<a title="EMJ 2.1 2017 page 4" href="http://viewer.zmags.com/publication/f42cbf2e?page=4"> EDITORIAL BOARD EDITOR-IN-CHIEF Prof Markus Pec</a>
<a title="EMJ 2.1 2017 page 5" href="http://viewer.zmags.com/publication/f42cbf2e?page=5"> EUROPEAN MEDICAL JOURNAL AIMS AND SCOPE • T</a>
<a title="EMJ 2.1 2017 page 6" href="http://viewer.zmags.com/publication/f42cbf2e?page=6"> EUROPEAN MEDICAL JOURNAL 2.1 MARCH 2017 Director</a>
<a title="EMJ 2.1 2017 page 7" href="http://viewer.zmags.com/publication/f42cbf2e?page=7"> Welcome Hello and welcome to the first edition </a>
<a title="EMJ 2.1 2017 page 8" href="http://viewer.zmags.com/publication/f42cbf2e?page=8"> Bosulif (bosutinib): Helping you give the righ</a>
<a title="EMJ 2.1 2017 page 9" href="http://viewer.zmags.com/publication/f42cbf2e?page=9"> Foreword </a>
<a title="EMJ 2.1 2017 page 10" href="http://viewer.zmags.com/publication/f42cbf2e?page=10"> Available Now E</a>
<a title="EMJ 2.1 2017 page 11" href="http://viewer.zmags.com/publication/f42cbf2e?page=11"> FEATURES Revolutionising Healthcare by Empowering</a>
<a title="EMJ 2.1 2017 page 12" href="http://viewer.zmags.com/publication/f42cbf2e?page=12"> CLIMATE CHANGE: WHAT CAN DOCTORS DO? *Thomas Mick</a>
<a title="EMJ 2.1 2017 page 13" href="http://viewer.zmags.com/publication/f42cbf2e?page=13"> Additionally, a secondary effect of climate chang</a>
<a title="EMJ 2.1 2017 page 14" href="http://viewer.zmags.com/publication/f42cbf2e?page=14"> REFERENCES 1. The Lancet. Health and climate cha</a>
<a title="EMJ 2.1 2017 page 15" href="http://viewer.zmags.com/publication/f42cbf2e?page=15"> Watch Our Exclusive Interviews from a Variety </a>
<a title="EMJ 2.1 2017 page 16" href="http://viewer.zmags.com/publication/f42cbf2e?page=16"> EDITOR’S PICK Estomba et al. discuss</a>
<a title="EMJ 2.1 2017 page 17" href="http://viewer.zmags.com/publication/f42cbf2e?page=17"> with intricate 3D microarchitecture and fabricate</a>
<a title="EMJ 2.1 2017 page 18" href="http://viewer.zmags.com/publication/f42cbf2e?page=18"> Table 1: Types of 3D printing methods useful in b</a>
<a title="EMJ 2.1 2017 page 19" href="http://viewer.zmags.com/publication/f42cbf2e?page=19"> 3D bioprinting materials are mostly limited </a>
<a title="EMJ 2.1 2017 page 20" href="http://viewer.zmags.com/publication/f42cbf2e?page=20"> WHAT ARE THE COSTS INVOLVED IN 3D BIOPRINTING? C</a>
<a title="EMJ 2.1 2017 page 21" href="http://viewer.zmags.com/publication/f42cbf2e?page=21"> next 10 years, this proportion is expected to gro</a>
<a title="EMJ 2.1 2017 page 22" href="http://viewer.zmags.com/publication/f42cbf2e?page=22"> 2013;4(6):12-14. 31. Hoy MB. 3D printing: making </a>
<a title="EMJ 2.1 2017 page 23" href="http://viewer.zmags.com/publication/f42cbf2e?page=23"> europeanmedical-journal.com EUROPEAN UNION Invest</a>
<a title="EMJ 2.1 2017 page 24" href="http://viewer.zmags.com/publication/f42cbf2e?page=24"> HIDE AND SEEK: THE GAME BETWEEN CHRONIC LYMPHOCY</a>
<a title="EMJ 2.1 2017 page 25" href="http://viewer.zmags.com/publication/f42cbf2e?page=25"> antibody rituximab in combination with the purine</a>
<a title="EMJ 2.1 2017 page 26" href="http://viewer.zmags.com/publication/f42cbf2e?page=26"> Antigen ligation CD79A/B BCR P </a>
<a title="EMJ 2.1 2017 page 27" href="http://viewer.zmags.com/publication/f42cbf2e?page=27"> The reduction of tumour burden with B</a>
<a title="EMJ 2.1 2017 page 28" href="http://viewer.zmags.com/publication/f42cbf2e?page=28"> has been described as a common resistance m</a>
<a title="EMJ 2.1 2017 page 29" href="http://viewer.zmags.com/publication/f42cbf2e?page=29"> haematological malignancies. The results from tho</a>
<a title="EMJ 2.1 2017 page 30" href="http://viewer.zmags.com/publication/f42cbf2e?page=30"> Labeling That the Bruton Tyrosine Kinase Inhibito</a>
<a title="EMJ 2.1 2017 page 31" href="http://viewer.zmags.com/publication/f42cbf2e?page=31"> HAEMANGIOMA: A REVIEW OF THE LITERATUR</a>
<a title="EMJ 2.1 2017 page 32" href="http://viewer.zmags.com/publication/f42cbf2e?page=32"> have both deep and superficial components. Ne</a>
<a title="EMJ 2.1 2017 page 33" href="http://viewer.zmags.com/publication/f42cbf2e?page=33"> column.10 These predominantly affect the thoracic</a>
<a title="EMJ 2.1 2017 page 34" href="http://viewer.zmags.com/publication/f42cbf2e?page=34"> Figure 2: Preoperative picture of swelling. </a>
<a title="EMJ 2.1 2017 page 35" href="http://viewer.zmags.com/publication/f42cbf2e?page=35"> REFERENCES 1. Richter GT, Friedman AB. Hemangiom</a>
<a title="EMJ 2.1 2017 page 36" href="http://viewer.zmags.com/publication/f42cbf2e?page=36"> TRANSCATHETER REPAIR OF CONGENITAL HEA</a>
<a title="EMJ 2.1 2017 page 37" href="http://viewer.zmags.com/publication/f42cbf2e?page=37"> double disc nitinol mesh. The device is securely </a>
<a title="EMJ 2.1 2017 page 38" href="http://viewer.zmags.com/publication/f42cbf2e?page=38"> compression of the AV node and subsequently</a>
<a title="EMJ 2.1 2017 page 39" href="http://viewer.zmags.com/publication/f42cbf2e?page=39"> A B C D Figure 2: Device closure of a ventricul</a>
<a title="EMJ 2.1 2017 page 40" href="http://viewer.zmags.com/publication/f42cbf2e?page=40"> a) Small PDA <3 mm are closed with Cook’s coils,</a>
<a title="EMJ 2.1 2017 page 41" href="http://viewer.zmags.com/publication/f42cbf2e?page=41"> A B Figure 3: Device closure of a patent arteri</a>
<a title="EMJ 2.1 2017 page 42" href="http://viewer.zmags.com/publication/f42cbf2e?page=42"> after several months for a bilateral cavopulmonar</a>
<a title="EMJ 2.1 2017 page 43" href="http://viewer.zmags.com/publication/f42cbf2e?page=43"> Currently, this procedure can only be done </a>
<a title="EMJ 2.1 2017 page 44" href="http://viewer.zmags.com/publication/f42cbf2e?page=44"> 29. Kutshe LM, Van Mierop LH. Anatomy and pathog</a>
<a title="EMJ 2.1 2017 page 45" href="http://viewer.zmags.com/publication/f42cbf2e?page=45"> ANAESTHESIA TECHNIQUES IN TRANSFEMORAL TRANSCATHE</a>
<a title="EMJ 2.1 2017 page 46" href="http://viewer.zmags.com/publication/f42cbf2e?page=46"> THE IMPORTANT ROLE OF THE ANAESTHETIST IN TRANSCA</a>
<a title="EMJ 2.1 2017 page 47" href="http://viewer.zmags.com/publication/f42cbf2e?page=47"> approach for all patients. All procedures w</a>
<a title="EMJ 2.1 2017 page 48" href="http://viewer.zmags.com/publication/f42cbf2e?page=48"> Ben-Dor et al.17 also demonstrated the feasibilit</a>
<a title="EMJ 2.1 2017 page 49" href="http://viewer.zmags.com/publication/f42cbf2e?page=49"> REFERENCES 1. Billings FT et al. Transcatheter a</a>
<a title="EMJ 2.1 2017 page 50" href="http://viewer.zmags.com/publication/f42cbf2e?page=50"> NEW DRUG TREATMENTS FOR OSTEOARTHRITIS: </a>
<a title="EMJ 2.1 2017 page 51" href="http://viewer.zmags.com/publication/f42cbf2e?page=51"> with or without an effect on pain (DMOADs). Exist</a>
<a title="EMJ 2.1 2017 page 52" href="http://viewer.zmags.com/publication/f42cbf2e?page=52"> Ligament and soft tissue Inflammation </a>
<a title="EMJ 2.1 2017 page 53" href="http://viewer.zmags.com/publication/f42cbf2e?page=53"> to be the important aggrecanase in humans.21,22 S</a>
<a title="EMJ 2.1 2017 page 54" href="http://viewer.zmags.com/publication/f42cbf2e?page=54"> In a previous study Verbruggen et al.47 had repor</a>
<a title="EMJ 2.1 2017 page 55" href="http://viewer.zmags.com/publication/f42cbf2e?page=55"> Pain is the leading symptom for patients; whilst </a>
<a title="EMJ 2.1 2017 page 56" href="http://viewer.zmags.com/publication/f42cbf2e?page=56"> Who will benefit from these drugs? The majority of</a>
<a title="EMJ 2.1 2017 page 57" href="http://viewer.zmags.com/publication/f42cbf2e?page=57"> Osteoarthritis of the Knee. Abstract 2350. ACR/AR</a>
<a title="EMJ 2.1 2017 page 58" href="http://viewer.zmags.com/publication/f42cbf2e?page=58"> of Spironolactone on Pain in Older People W</a>
<a title="EMJ 2.1 2017 page 59" href="http://viewer.zmags.com/publication/f42cbf2e?page=59"> EUROPEAN MEDICAL JOURNAL provides influential arti</a>
<a title="EMJ 2.1 2017 page 60" href="http://viewer.zmags.com/publication/f42cbf2e?page=60"> CONTEMPORARY DRUG-ELUTING </a>
<a title="EMJ 2.1 2017 page 61" href="http://viewer.zmags.com/publication/f42cbf2e?page=61"> components in the DES system (e.g. the metallic b</a>
<a title="EMJ 2.1 2017 page 62" href="http://viewer.zmags.com/publication/f42cbf2e?page=62"> Table 1: Comparison of contemporary drug-eluting </a>
<a title="EMJ 2.1 2017 page 63" href="http://viewer.zmags.com/publication/f42cbf2e?page=63"> The development of locally eluted sirol</a>
<a title="EMJ 2.1 2017 page 64" href="http://viewer.zmags.com/publication/f42cbf2e?page=64"> efficacy.24 Vascular responses in the porcine mod</a>
<a title="EMJ 2.1 2017 page 65" href="http://viewer.zmags.com/publication/f42cbf2e?page=65"> BMS SES control SRL Figure 2: Poorly formed endo</a>
<a title="EMJ 2.1 2017 page 66" href="http://viewer.zmags.com/publication/f42cbf2e?page=66"> in fact be the most important mechanism by which </a>
<a title="EMJ 2.1 2017 page 67" href="http://viewer.zmags.com/publication/f42cbf2e?page=67"> endothelial barrier formation and likely contribu</a>
<a title="EMJ 2.1 2017 page 68" href="http://viewer.zmags.com/publication/f42cbf2e?page=68"> on fluorinated copolymer and phosph</a>
<a title="EMJ 2.1 2017 page 69" href="http://viewer.zmags.com/publication/f42cbf2e?page=69"> DOES RACE/ETHNICITY HAVE A </a>
<a title="EMJ 2.1 2017 page 70" href="http://viewer.zmags.com/publication/f42cbf2e?page=70"> findings can be attributed to religious cust</a>
<a title="EMJ 2.1 2017 page 71" href="http://viewer.zmags.com/publication/f42cbf2e?page=71"> similar to each other and also to the reported pr</a>
<a title="EMJ 2.1 2017 page 72" href="http://viewer.zmags.com/publication/f42cbf2e?page=72"> in the age-specific PSA reference range is well kn</a>
<a title="EMJ 2.1 2017 page 73" href="http://viewer.zmags.com/publication/f42cbf2e?page=73"> Autonomic nervous system hyperactivity is</a>
<a title="EMJ 2.1 2017 page 74" href="http://viewer.zmags.com/publication/f42cbf2e?page=74"> causally related to the development of BPH by an </a>
<a title="EMJ 2.1 2017 page 75" href="http://viewer.zmags.com/publication/f42cbf2e?page=75"> to explore genetic contributions to dispa</a>
<a title="EMJ 2.1 2017 page 76" href="http://viewer.zmags.com/publication/f42cbf2e?page=76"> ANTIPHOSPHOLIPID SYNDROME AND THE </a>
<a title="EMJ 2.1 2017 page 77" href="http://viewer.zmags.com/publication/f42cbf2e?page=77"> thrombosis (DVT), thrombocytopenia, live</a>
<a title="EMJ 2.1 2017 page 78" href="http://viewer.zmags.com/publication/f42cbf2e?page=78"> (Group 3); chronic thromboembolic PH (CTEPH) (Gro</a>
<a title="EMJ 2.1 2017 page 79" href="http://viewer.zmags.com/publication/f42cbf2e?page=79"> of three different histopathological patterns see</a>
<a title="EMJ 2.1 2017 page 80" href="http://viewer.zmags.com/publication/f42cbf2e?page=80"> clinical status and recurrence of thrombotic even</a>
<a title="EMJ 2.1 2017 page 81" href="http://viewer.zmags.com/publication/f42cbf2e?page=81"> REFERENCES 1. Miyakis S et al. In</a>
<a title="EMJ 2.1 2017 page 82" href="http://viewer.zmags.com/publication/f42cbf2e?page=82"> with systemic vasculitis. Arch Pathol Lab Med. 19</a>
<a title="EMJ 2.1 2017 page 83" href="http://viewer.zmags.com/publication/f42cbf2e?page=83"> CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 </a>
<a title="EMJ 2.1 2017 page 84" href="http://viewer.zmags.com/publication/f42cbf2e?page=84"> trials, three have included a dipeptidyl peptidas</a>
<a title="EMJ 2.1 2017 page 85" href="http://viewer.zmags.com/publication/f42cbf2e?page=85"> The three DPP-4 inhibitor trials </a>
<a title="EMJ 2.1 2017 page 86" href="http://viewer.zmags.com/publication/f42cbf2e?page=86"> similar in the two groups. Rates of new o</a>
<a title="EMJ 2.1 2017 page 87" href="http://viewer.zmags.com/publication/f42cbf2e?page=87"> TREATMENT OF HYPERTENSION Elevated blood pressur</a>
<a title="EMJ 2.1 2017 page 88" href="http://viewer.zmags.com/publication/f42cbf2e?page=88"> SUMMARY To protect patients with Type 2 diabetes</a>
<a title="EMJ 2.1 2017 page 89" href="http://viewer.zmags.com/publication/f42cbf2e?page=89"> Toxicol. 2017; 57:223-44. 22. Sabatine MS et </a>
<a title="EMJ 2.1 2017 page 90" href="http://viewer.zmags.com/publication/f42cbf2e?page=90"> STATE-OF-THE-ART ADVANCES IN DUCH</a>
<a title="EMJ 2.1 2017 page 91" href="http://viewer.zmags.com/publication/f42cbf2e?page=91"> gene is relatively high and about one-third of ca</a>
<a title="EMJ 2.1 2017 page 92" href="http://viewer.zmags.com/publication/f42cbf2e?page=92"> reliable and cost-effective test to detect deleti</a>
<a title="EMJ 2.1 2017 page 93" href="http://viewer.zmags.com/publication/f42cbf2e?page=93"> Table 1: Summary of adverse effects of corticoste</a>
<a title="EMJ 2.1 2017 page 94" href="http://viewer.zmags.com/publication/f42cbf2e?page=94"> centred around early detection of disea</a>
<a title="EMJ 2.1 2017 page 95" href="http://viewer.zmags.com/publication/f42cbf2e?page=95"> Table 3: List of Duchenne muscular dystrophy stud</a>
<a title="EMJ 2.1 2017 page 96" href="http://viewer.zmags.com/publication/f42cbf2e?page=96"> Table 3 continued. Approach Target Select</a>
<a title="EMJ 2.1 2017 page 97" href="http://viewer.zmags.com/publication/f42cbf2e?page=97"> This includes clinical care, corticosteroid treat</a>
<a title="EMJ 2.1 2017 page 98" href="http://viewer.zmags.com/publication/f42cbf2e?page=98"> the importance of disease-specific biomarkers </a>
<a title="EMJ 2.1 2017 page 99" href="http://viewer.zmags.com/publication/f42cbf2e?page=99"> muscular dystrophy. Neurology. 1991; 41(12):18</a>
<a title="EMJ 2.1 2017 page 100" href="http://viewer.zmags.com/publication/f42cbf2e?page=100"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NEW</a>